Venker Eric's Form 4 filing
Roivant Sciences Ltd. (ROIV) · filed Jul 29, 2026
- Accession no.
- 0001140361-26-030107
- Filed
- Jul 29, 2026, 9:00 PM ET
- Trade date
- Jul 27, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $6.99M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Venker EricCIK 0001801917 | Officer (President & Immunovant CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 27, 2026 | Common Shares | MOption exerciseAcquired | +200,000 | $3.85 | +$770,000 | 1,813,063 | Direct | |
| Jul 27, 2026 | Common Shares | SSaleDisposed | −200,000 | $34.95 | −$6,990,000 | 1,613,063 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 27, 2026 | Common Stock | MOption exerciseDisposed | −200,000 | $0.00 | $0 | 4,044,834 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.